Skip to main content
. Author manuscript; available in PMC: 2022 Jun 10.
Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1586–1594. doi: 10.1158/1078-0432.CCR-21-3874

Figure 2. Pharmacokinetics of each agent.

Figure 2.

A, Plasma concentrations of total vismodegib in 8 patients in Phase Ib. B-C, plasma concentrations of total RO4929097 on the monotherapy arm (B) and combination therapy arm (C), in 10 and 12 patients, respectively, in Phase II. Each line represents an individual patient.